Thread by @SRAnesthesiaICU

#Etomidate and mortality in critically ill patients

Etomidate is a common induction agent but controversy exists about its effects on outcomes

Our meta-analysis found a high probability that etomidate increases mortality (NNH 31)

🧵Thread 1/6 🔗sciencedirect.com/science/articl… #FOAMcc

2/

PICOS of this SR/MA

P: Critically ill patients
I: #Etomidate as an induction agent for intubation
C: Any comparator
O: Mortality at the main timepoint defined by authors
S: Randomized controlled trials

11 RCTs with 2704 patients were included

#FOAMcc

3/

#Etomidate was associated with significantly increased mortality (23% vs 20%; risk ratio = 1.16 [1.01–1.33]; P = 0.03)

The number needed to harm was 31

The probabilities of any increase and a 1% increase (NNH ≤100) in mortality were 98.1% and 92.1%, respectively.

#FOAMcc

4/

Sensitivity analyses confirmed main results

Direction/magnitude consistent for mortality at longest follow-up available even if statistical significance was lost (27% vs 25%; RR=1.07 [0.95–1.21]; P=0.27), corresponding to 86% probability of any harm from #Etomidate

#FOAMcc

5/

#Etomidate was associated with a significantly increased risk of adrenal insufficiency (21% vs. 10%; risk ratio = 2.01 [1.59–2.56]; P < 0.001), confirming the findings of previous meta-analyses.

#FOAMcc

6/

🔹Our meta-analysis showed a high likelihood that etomidate was associated with an increased risk of mortality and adrenal insufficiency

🔹Future research is warranted to investigate the optimal induction strategy for critically ill patients

#FOAMcc

https://twitter.com/SRAnesthesiaICU/status/1652708942164656131?s=20